Zimmer Biomet reports Q1 EPS $2.09, consensus $1.86

Reports Q1 revenue $2.09B, consensus $2.07B. “We are off to a solid start to the year – strategically, operationally and financially,” said Ivan Tornos, chairman, president and CEO of Zimmer Biomet (ZBH). “Our first quarter results reflect healthy end markets, continued momentum from our recently launched products and disciplined execution across the business. Given our progress and with our go-to-market transformation proceeding as planned, we are raising our adjusted EPS guidance and free cash flow expectations for the year. We remain confident that our strategy will position Zimmer Biomet for consistent, durable growth over the longer term.”